Barely months after reporting another successful year of record revenues and record earnings, Catalyst Pharmaceuticals Inc. (CPRX) has agreed to be acquired by Italy's Angelini Pharma S.p.A, for US$31.50 per share or a total equity value of US$4.1 billion.
Catalyst has a robust portfolio of products focused on the treatment of rare neuromuscular and neurological diseases. It markets Lambert-Eaton myasthenic syndrome drug FIRDAPSE, Duchenne Muscular Dystrophy drug AGAMREE, and antiepileptic drug FYCOMPA, the U.S. rights to which were acquired from Eisai in 2023.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.